Free Trial

Corcept Therapeutics (CORT) News Today

→ A Wave of Creative Destruction Set to Strike June 30 (From Banyan Hill Publishing) (Ad)
Free CORT Stock Alerts
$33.27
-1.21 (-3.51%)
(As of 02:33 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 7 at 10:30 AM | marketbeat.com
248,342 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Bought by Quantedge Capital Pte Ltd
Quantedge Capital Pte Ltd purchased a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 248,342 shares of the biotechnology company's stock, valued a
June 7 at 5:44 AM | americanbankingnews.com
Joseph Douglas Lyon Sells 5,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock
June 6 at 4:00 PM | stocknews.com
3 Biotech Stocks for Investing in the Future
June 6 at 8:26 AM | americanbankingnews.com
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock
June 6 at 7:54 AM | insidertrades.com
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares
June 6 at 7:36 AM | insidertrades.com
Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 5,000 Shares of Stock
June 6 at 2:34 AM | americanbankingnews.com
Truist Financial Reiterates "Buy" Rating for Corcept Therapeutics (NASDAQ:CORT)
June 5 at 10:17 PM | marketbeat.com
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $150,900.00 in Stock
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $30.18, for a total transaction of $150,900.00. Following the completion of the sale, the insider now directly owns 7,314 shares in the company, valued at approximately $220,736.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
June 5 at 3:49 PM | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month High at $34.39
Corcept Therapeutics (NASDAQ:CORT) Sets New 52-Week High at $34.39
June 4 at 10:43 AM | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up to $31.30
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up to $31.30
June 4 at 10:09 AM | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Receives "Buy" Rating from Truist Financial
Truist Financial restated a "buy" rating and issued a $65.00 price objective (up previously from $44.00) on shares of Corcept Therapeutics in a research note on Tuesday.
June 4 at 1:54 AM | americanbankingnews.com
Zacks Research Equities Analysts Reduce Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)
June 3, 2024 | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Trading 5.6% Higher
Corcept Therapeutics (NASDAQ:CORT) Trading 5.6% Higher
June 3, 2024 | globenewswire.com
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)
June 3, 2024 | marketbeat.com
Brokers Offer Predictions for Corcept Therapeutics Incorporated's Q4 2025 Earnings (NASDAQ:CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Research analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report released on Wednesday, May 29th. Zacks Research analyst K. Das now expects that the biotechnology company w
June 2, 2024 | marketbeat.com
Norges Bank Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
Norges Bank bought a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 757,490 shares of the biotechnology company's stock, valued at approximately $24,603,
June 2, 2024 | americanbankingnews.com
Brokers Offer Predictions for Corcept Therapeutics Incorporated's Q1 2025 Earnings (NASDAQ:CORT)
June 1, 2024 | americanbankingnews.com
Gary Charles Robb Sells 11,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock
May 31, 2024 | insidertrades.com
Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 11,000 Shares of Stock
May 31, 2024 | marketbeat.com
Corcept Therapeutics Incorporated (NASDAQ:CORT) Forecasted to Post Q1 2025 Earnings of $0.24 Per Share
Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at Zacks Research upped their Q1 2025 earnings per share estimates for Corcept Therapeutics in a report issued on Wednesday, May 29th. Zacks Research analyst K. Das now forecasts that the biotechnology comp
May 30, 2024 | americanbankingnews.com
Corcept Therapeutics' (CORT) "Buy" Rating Reaffirmed at HC Wainwright
May 29, 2024 | marketbeat.com
HC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT)
HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Corcept Therapeutics in a research note on Wednesday.
May 28, 2024 | marketwatch.com
Corcept Therapeutics Shares Rise 9% After Relacorilant Trial Meets Primary Endpoint
May 28, 2024 | msn.com
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
May 28, 2024 | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up to $27.52
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up to $27.52
May 28, 2024 | finance.yahoo.com
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
May 27, 2024 | marketbeat.com
Parallel Advisors LLC Has $122.39 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)
Parallel Advisors LLC raised its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 1.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,768,245 shares of the biotechnology company's stock a
May 26, 2024 | marketbeat.com
Assetmark Inc. Increases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
Assetmark Inc. boosted its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 221.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,101 shares of the biotechnology
May 23, 2024 | marketbeat.com
Charles Schwab Investment Management Inc. Raises Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)
Charles Schwab Investment Management Inc. grew its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 900,444 shares
May 22, 2024 | benzinga.com
LEONARD BAKER JR Makes A Tactical Move: Adds Corcept Therapeutics Stock Options To Portfolio
May 20, 2024 | marketbeat.com
Research Analysts Offer Predictions for Corcept Therapeutics Incorporated's FY2024 Earnings (NASDAQ:CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at Zacks Research issued their FY2024 EPS estimates for Corcept Therapeutics in a report issued on Thursday, May 16th. Zacks Research analyst K. Das forecasts that the biotechnology company will post earnin
May 19, 2024 | marketbeat.com
Victory Capital Management Inc. Sells 32,358 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Victory Capital Management Inc. reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 40.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,731 share
May 17, 2024 | marketbeat.com
Short Interest in Corcept Therapeutics Incorporated (NASDAQ:CORT) Declines By 6.3%
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 19,800,000 shares, a decrease of 6.3% from the April 15th total of 21,120,000 shares. Currently, 22.1% of the company's stock are sold short. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is presently 18.0 days.
May 17, 2024 | marketbeat.com
Corcept Therapeutics Incorporated to Post Q2 2024 Earnings of $0.20 Per Share, Zacks Research Forecasts (NASDAQ:CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities researchers at Zacks Research boosted their Q2 2024 earnings estimates for shares of Corcept Therapeutics in a note issued to investors on Thursday, May 16th. Zacks Research analyst K. Das now anticipates that the biotechnol
May 16, 2024 | insidertrades.com
Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 50,000 Shares of Stock
May 16, 2024 | marketbeat.com
Jump Financial LLC Buys Shares of 49,226 Corcept Therapeutics Incorporated (NASDAQ:CORT)
Jump Financial LLC bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 49,226 shares of the biotechnology company's stock, valued at approximat
May 14, 2024 | insidertrades.com
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $187,902.00 in Stock
May 13, 2024 | finance.yahoo.com
3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%
May 8, 2024 | marketbeat.com
New York State Common Retirement Fund Has $2.28 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)
New York State Common Retirement Fund trimmed its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 34.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,235 shares of the biotechnology comp
May 7, 2024 | insidertrades.com
Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $281,580.00 in Stock
May 6, 2024 | marketbeat.com
Insider Selling: Corcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells 10,830 Shares of Stock
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider Joseph Douglas Lyon sold 10,830 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $26.00, for a total value of $281,580.00. Following the completion of the sale, the insider now directly owns 7,314 shares of the company's stock, valued at approximately $190,164. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
May 3, 2024 | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Shares Down 4.5%
Corcept Therapeutics (NASDAQ:CORT) Shares Down 4.5%
May 3, 2024 | finance.yahoo.com
Corcept Therapeutics First Quarter 2024 Earnings: Beats Expectations
May 3, 2024 | marketbeat.com
Q2 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lifted by Analyst
Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Investment analysts at HC Wainwright increased their Q2 2024 EPS estimates for shares of Corcept Therapeutics in a report released on Thursday, May 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company
May 2, 2024 | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Price Target Raised to $40.00
HC Wainwright lifted their price objective on shares of Corcept Therapeutics from $38.00 to $40.00 and gave the stock a "buy" rating in a research report on Thursday.
May 2, 2024 | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Issues Earnings Results
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.04. Corcept Therapeutics had a net margin of 21.86% and a return on equity of 21.98%. The company had revenue of $146.80 million during the quarter, compared to analyst estimates of $141.19 million. During the same quarter last year, the business posted $0.14 EPS. Corcept Therapeutics's quarterly revenue was up 38.9% compared to the same quarter last year.
May 2, 2024 | marketbeat.com
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up on Strong Earnings
Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up After Earnings Beat
May 2, 2024 | gurufocus.com
Q1 2024 Corcept Therapeutics Inc Earnings Call Transcript
May 1, 2024 | investorplace.com
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 1, 2024 | sfgate.com
Corcept: Q1 Earnings Snapshot
Get Corcept Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Top 5 AI Stocks to Buy for 2024 (Ad)

The electric vehicle boom is accelerating – and fast.

Click to View The 5 Best AI Stocks to Invest In

CORT Media Mentions By Week

CORT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CORT
News Sentiment
▼
0.38

0.73
▲
Average
Medical
News Sentiment

CORT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CORT Articles
This Week
▼
26

5
▲
CORT Articles
Average Week

Get Corcept Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:CORT) was last updated on 6/7/2024 by MarketBeat.com Staff

From Our Partners
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Elon Musk’s Final Masterpiece: “X-9840”
The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...
Paradigm Press | Sponsored
What Nvidia insiders don’t want you to know
If you missed out on Nvidia, don't worry. A 244-year-old pattern is about to trigger a $25.6 trillion AI surge...
Behind the Markets | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...
Crypto Swap Profits | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored